Chemokines in transplantation: What can atypical receptors teach us about anti-inflammatory therapy?

Transplantation Reviews

Volumn 25, Issue 4, 2011, Pages 136-144

  O'Boyle, Graeme ^a   Ali, S ^a   Kirby, J A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CCX 282; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; MARAVIROC; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANTIINFLAMMATORY ACTIVITY; DRUG TARGETING; GRAFT REJECTION; HUMAN; INFLAMMATION; LEUKOCYTE MIGRATION; LIGAND BINDING; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; TRANSPLANTATION;

EID: 80052992000     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2010.10.005     Document Type: Review

References (99)

1. Pease J.E., Williams T.J. The attraction of chemokines as a target for specific anti-inflammatory therapy. Br J Pharmacol 2006, 147(Suppl 1):S212-S221.
2. Bacon K., Baggiolini M., Broxmeyer H., et al. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 2002, 22:1067-1068.
3. Thelen M., Thelen S. CXCR7, CXCR4 and CXCL12: an eccentric trio?. J Neuroimmunol 2008, 198:9-13.
4. Moser B., Wolf M., Walz A., Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004, 25:75-84.
5. Avlonitis V.S., Wigfield C.H., Golledge H.D., Kirby J.A., Dark J.H. Early hemodynamic injury during donor brain death determines the severity of primary graft dysfunction after lung transplantation. Am J Transplant 2007, 7:83-90.
6. el-Sawy T., Fahmy N.M., Fairchild R.L. Chemokines: directing leukocyte infiltration into allografts. Curr Opin Immunol 2002, 14:562-568.
7. Walsh P.T., Strom T.B., Turka L.A. Routes to transplant tolerance versus rejection; the role of cytokines. Immunity 2004, 20:121-131.
8. Russell M.E., Adams D.H., Wyner L.R., Yamashita Y., Halnon N.J., Karnovsky M.J. Early and persistent induction of monocyte chemoattractant protein 1 in rat cardiac allografts. Proc Natl Acad Sci U S A 1993, 90:6086-6090.
9. Fairchild R.L. Raising the direction signposts that guide T cell trafficking into allografts. Transplantation 2005, 79:646-647.
10. Ali S., Malik G., Burns A., Robertson H., Kirby J.A. Renal transplantation: examination of the regulation of chemokine binding during acute rejection. Transplantation 2005, 79:672-679.
11. Belperio J.A., Ardehali A. Chemokines and transplant vasculopathy. Circ Res 2008, 103:454-466.
12. Mitchell R.N. Allograft arteriopathy: pathogenesis update. Cardiovasc Pathol 2004, 13:33-40.
13. Mantovani A., Locati M., Vecchi A., Sozzani S., Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 2001, 22:328-336.
14. Colotta F., Re F., Muzio M., et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science (New York, NY) 1993, 261:472-475.
15. Comerford I., Nibbs R.J. Post-translational control of chemokines: a role for decoy receptors?. Immunol Lett 2005, 96:163-174.
16. Horuk R., Martin A., Hesselgesser J., et al. The Duffy antigen receptor for chemokines: structural analysis and expression in the brain. J Leukoc Biol 1996, 59:29-38.
17. Nibbs R.J., McLean P., McCulloch C., et al. Structure-function dissection of D6, an atypical scavenger receptor. Methods Enzymol 2009, 460:245-261.
18. Tournamille C., Blancher A., Le Van Kim C., et al. Sequence, evolution and ligand binding properties of mammalian Duffy antigen/receptor for chemokines. Immunogenetics 2004, 55:682-694.
19. Lu Z.H., Wang Z.X., Horuk R., et al. The promiscuous chemokine binding profile of the Duffy antigen/receptor for chemokines is primarily localized to sequences in the amino-terminal domain. J Biol Chem 1995, 270:26239-26245.
20. Blackburn P.E., Simpson C.V., Nibbs R.J., et al. Purification and biochemical characterization of the D6 chemokine receptor. Biochem J 2004, 379:263-272.
21. Neote K., Darbonne W., Ogez J., Horuk R., Schall T.J. Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells. J Biol Chem 1993, 268:12247-12249.
22. Peiper S.C., Wang Z.X., Neote K., et al. The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor. J Exp Med 1995, 181:1311-1317.
23. Gardner L., Patterson A.M., Ashton B.A., Stone M.A., Middleton J. The human Duffy antigen binds selected inflammatory but not homeostatic chemokines. Biochem Biophys Res Commun 2004, 321:306-312.
24. Nibbs R.J., Wylie S.M., Yang J., Landau N.R., Graham G.J. Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6. J Biol Chem 1997, 272:32078-32083.
25. Nibbs R.J., Kriehuber E., Ponath P.D., et al. The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am J Pathol 2001, 158:867-877.
26. Madigan J., Freeman D.J., Menzies F., et al. Chemokine scavenger D6 is expressed by trophoblasts and AIDS the survival of mouse embryos transferred into allogeneic recipients. J Immunol 2010, 184:3202-3212.
27. McKimmie C.S., Graham G.J. Leucocyte expression of the chemokine scavenger D6. Biochem Soc Trans 2006, 34:1002-1004.
28. Bradford L., Marshall H., Robertson H., et al. Cardiac allograft rejection: examination of the expression and function of the decoy chemokine receptor D6. Transplantation 2010, 89:1411-1416.
29. Gosling J., Dairaghi D.J., Wang Y., et al. Cutting edge: identification of a novel chemokine receptor that binds dendritic cell? and T cell-active chemokines including ELC, SLC, and TECK. J Immunol 2000, 164:2851-2856.
30. Kriegova E., Tsyrulnyk A., Arakelyan A., et al. Expression of CCX CKR in pulmonary sarcoidosis. Inflamm Res 2006, 55:441-445.
31. Balabanian K., Lagane B., Infantino S., et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005, 280:35760-35766.
32. Comerford I., Litchfield W., Harata-Lee Y., Nibbs R.J., McColl S.R. Regulation of chemotactic networks by "atypical" receptors. Bioessays 2007, 29:237-247.
33. Horuk R., Colby T.J., Darbonne W.C., Schall T.J., Neote K. The human erythrocyte inflammatory peptide (chemokine) receptor. Biochemical characterization, solubilization, and development of a binding assay for the soluble receptor. Biochemistry 1993, 32:5733-5738.
34. Neote K., Mak J.Y., Kolakowski L.F., Schall T.J. Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor. Blood 1994, 84:44-52.
35. Horne K., Woolley I.J. Shedding light on DARC: the role of the Duffy antigen/receptor for chemokines in inflammation, infection and malignancy. Inflamm Res 2009, 58:431-435.
36. Tournamille C., Colin Y., Cartron J.P., Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet 1995, 10:224-228.
37. Vergara C., Tsai Y.J., Grant A.V., et al. Gene encoding Duffy antigen/receptor for chemokines is associated with asthma and IgE in three populations. Am J Respir Crit Care Med 2008, 178:1017-1022.
38. Segerer S., Regele H., Mac K.M., et al. The Duffy antigen receptor for chemokines is up-regulated during acute renal transplant rejection and crescentic glomerulonephritis. Kidney Int 2000, 58:1546-1556.
39. Segerer S., Cui Y., Eitner F., et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 2001, 37:518-531.
40. Segerer S., Bohmig G.A., Exner M., et al. When renal allografts turn DARC. Transplantation 2003, 75:1030-1034.
41. Akalin E., Neylan J.F. The influence of Duffy blood group on renal allograft outcome in African Americans. Transplantation 2003, 75:1496-1500.
42. Mange K.C., Prak E.L., Kamoun M., et al. Duffy antigen receptor and genetic susceptibility of African Americans to acute rejection and delayed function. Kidney Int 2004, 66:1187-1192.
43. Mayr F.B., Spiel A.O., Leitner J.M., et al. Duffy antigen modifies the chemokine response in human endotoxemia. Crit Care Med 2008, 36:159-165.
44. Mangalmurti N.S., Xiong Z., Hulver M., et al. Loss of red cell chemokine scavenging promotes transfusion-related lung inflammation. Blood 2009, 113:1158-1166.
45. Mayr F.B., Spiel A.O., Leitner J.M., et al. Influence of the Duffy antigen on pharmacokinetics and pharmacodynamics of recombinant monocyte chemoattractant protein (MCP-1, CCL-2) in vivo. Int J Immunopathol Pharmacol 2009, 22:615-625.
46. Schnabel R.B., Baumert J., Barbalic M., et al. Duffy antigen receptor for chemokines (DARC) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 2009, 5289-5299.
47. Zarbock A, Bishop J, Muller H, et al. Chemokine homeostasis vs. chemokine presentation during severe acute lung injury: the other side of the Duffy antigen receptor for chemokines. Am J Physiol 298:L462-L471.
48. Chaudhuri A., Rodriguez M., Zbrzezna V., Luo H., Pogo A.O., Banerjee D. Induction of Duffy gene (FY) in human endothelial cells and in mouse. Cytokine 2003, 21:137-148.
49. Middleton J., Patterson A.M., Gardner L., Schmutz C., Ashton B.A. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002, 100:3853-3860.
50. Rot A. Contribution of Duffy antigen to chemokine function. Cytokine Growth Factor Rev 2005, 16:687-694.
51. Pruenster M., Mudde L., Bombosi P., et al. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol 2009, 10:101-108.
52. Geleff S., Draganovici D., Jaksch P., Segerer S. The role of chemokine receptors in acute lung allograft rejection. Eur Respir J 2010, 35:167-175.
53. Bruhl H., Vielhauer V., Weiss M., Mack M., Schlondorff D., Segerer S. Expression of DARC, CXCR3 and CCR5 in giant cell arteritis. Rheumatology (Oxford) 2005, 44:309-313.
54. Zarbock A., Schmolke M., Bockhorn S.G., et al. The Duffy antigen receptor for chemokines in acute renal failure: a facilitator of renal chemokine presentation. Crit Care Med 2007, 35:2156-2163.
55. Vielhauer V., Allam R., Lindenmeyer M.T., et al. Efficient renal recruitment of macrophages and T cells in mice lacking the duffy antigen/receptor for chemokines. Am J Pathol 2009, 175:119-131.
56. Nibbs R.J., Wylie S.M., Pragnell I.B., Graham G.J. Cloning and characterization of a novel murine beta chemokine receptor, D6. Comparison to three other related macrophage inflammatory protein-1alpha receptors, CCR-1, CCR-3, and CCR-5. J Biol Chem 1997, 272:12495-12504.
57. Galliera E., Jala V.R., Trent J.O., et al. beta-Arrestin-dependent constitutive internalization of the human chemokine decoy receptor D6. J Biol Chem 2004, 279:25590-25597.
58. Weber M., Blair E., Simpson C.V., et al. The chemokine receptor D6 constitutively traffics to and from the cell surface to internalize and degrade chemokines. Mol Biol Cell 2004, 15:2492-2508.
59. Graham G.J. D6 and the atypical chemokine receptor family: novel regulators of immune and inflammatory processes. Eur J Immunol 2009, 39:342-351.
60. Gerard C. Inflammatory chemokines: tuned in, turned on, dropped out. Nat Immunol 2005, 6:366-368.
61. Jamieson T., Cook D.N., Nibbs R.J., et al. The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol 2005, 6:403-411.
62. Martinez de la Torre Y., Locati M., Buracchi C., et al. Increased inflammation in mice deficient for the chemokine decoy receptor D6. Eur J Immunol 2005, 35:1342-1346.
63. Liu L., Graham G.J., Damodaran A., et al. Cutting edge: the silent chemokine receptor D6 is required for generating T cell responses that mediate experimental autoimmune encephalomyelitis. J Immunol 2006, 177:17-21.
64. Martinez de la Torre Y., Buracchi C., Borroni E.M., et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci U S A 2007, 104:2319-2324.
65. Nibbs R.J., Gilchrist D.S., King V., et al. The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest 2007, 117:1884-1892.
66. Wu F.Y., Ou Z.L., Feng L.Y., et al. Chemokine decoy receptor d6 plays a negative role in human breast cancer. Mol Cancer Res 2008, 6:1276-1288.
67. Whitehead G.S., Wang T., DeGraff L.M., et al. The chemokine receptor D6 has opposing effects on allergic inflammation and airway reactivity. Am J Respir Crit Care Med 2007, 175:243-249.
68. Di Liberto D., Locati M., Caccamo N., et al. Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in Mycobacterium tuberculosis infection. J Exp Med 2008, 205:2075-2084.
69. Berres M.L., Trautwein C., Zaldivar M.M., et al. The chemokine scavenging receptor D6 limits acute toxic liver injury in vivo. Biol Chem 2009, 390:1039-1045.
70. Vetrano S., Borroni E.M., Sarukhan A., et al. The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut 2010, 59:197-206.
71. Bordon Y., Hansell C.A., Sester D.P., Clarke M., Mowat A.M., Nibbs R.J. The atypical chemokine receptor D6 contributes to the development of experimental colitis. J Immunol 2009, 182:5032-5040.
72. Graham G.J., McKimmie C.S. Chemokine scavenging by D6: a movable feast?. Trends Immunol 2006, 27:381-386.
73. Trujillo G., O'Connor E.C., Kunkel S.L., Hogaboam C.M. A novel mechanism for CCR4 in the regulation of macrophage activation in bleomycin-induced pulmonary fibrosis. Am J Pathol 2008, 172:1209-1221.
74. McKimmie C.S., Fraser A.R., Hansell C., et al. Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1. J Immunol 2008, 181:3353-3363.
75. Townson J.R., Nibbs R.J. Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3beta/mCCL19: comparison to human CCX-CKR. Eur J Immunol 2002, 32:1230-1241.
76. Haraldsen G., Rot A. Coy decoy with a new ploy: interceptor controls the levels of homeostatic chemokines. Eur J Immunol 2006, 36:1659-1661.
77. Comerford I., Milasta S., Morrow V., Milligan G., Nibbs R. The chemokine receptor CCX-CKR mediates effective scavenging of CCL19 in vitro. Eur J Immunol 2006, 36:1904-1916.
78. Feng L.Y., Ou Z.L., Wu F.Y., Shen Z.Z., Shao Z.M. Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res 2009, 15:2962-2970.
79. Law N.M., Rosenzweig S.A. Characterization of the G-protein linked orphan receptor GPRN1/RDC1. Biochem Biophys Res Commun 1994, 201:458-465.
80. Burns J.M., Summers B.C., Wang Y., et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006, 203:2201-2213.
81. Levoye A., Balabanian K., Baleux F., Bachelerie F., Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009, 113:6085-6093.
82. Rajagopal S., Kim J., Ahn S., et al. Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci USA 2010, 107:628-632.
83. Naumann U., Cameroni E., Pruenster M., et al. functions as a scavenger for CXCL12 and CXCL11. PloS one 2010, 5:e9175.
84. Patel M., McInnes I.B., Graham G. Atypical chemokine receptors in inflammatory disease. Curr Mol Med 2009, 9:86-93.
85. Leick M., Catusse J., Follo M., et al. CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B. Immunology 2009.
86. Zabel B.A., Nakae S., Zuniga L., et al. Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp Med 2008, 205:2207-2220.
87. Borroni E.M., Bonecchi R. Shaping the gradient by nonchemotactic chemokine receptors. Cell Adhes Migration 2009, 3:146-147.
88. Proudfoot A.E. Chemokine receptors: multifaceted therapeutic targets. Nat Rev 2002, 2:106-115.
89. Schenk A.D., Rosenblum J.M., Fairchild R.L. Chemokine-directed strategies to attenuate allograft rejection. Clin Lab Med 2008, 28:441-454. vii.
90. Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov 2009, 8:23-33.
91. Donzella G.A., Schols D., Lin S.W., et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998, 4:72-77.
92. Pease J.E., Horuk R. Chemokine receptor antagonists: part 2. Expert Opin Ther Pat 2009, 19:199-221.
93. Pease J.E., Horuk R. Chemokine receptor antagonists: part 1. Expert Opin Ther Pat 2009, 19:39-58.
94. Proudfoot A.E., Power C.A., Schwarz M.E. Anti-chemokine small molecule drugs: a promising future?. Mol Immunol 2010, 19:345-355.
95. Ali S., O'Boyle G., Mellor P., Kirby J.A. An apparent paradox: chemokine receptor agonists can be used for anti-inflammatory therapy. Mol Immunol 2007, 44:1477-1482.
96. Springael J.Y., Urizar E., Parmentier M. Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev 2005, 16:611-623.
97. Chakera A., Seeber R.M., John A.E., Eidne K.A., Greaves D.R. The duffy antigen/receptor for chemokines exists in an oligomeric form in living cells and functionally antagonizes CCR5 signaling through hetero-oligomerization. Mol Pharmacol 2008, 73:1362-1370.
98. Panaro M.A., Calvello R., Lisi S., Saccia M., Cianciulli A., Cavallo P. Chemokine receptor-related viral protein products. Immunopharmacol Immunotoxicol 2010, 32:17-27.
99. Deruaz M., Frauenschuh A., Alessandri A.L., et al. Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med 2008, 205:2019-2031.